Sean Werner, CTO, BioLife Solutions | Onyx Live | ISCT Dublin 2026
Most cell therapies arrive at the patient frozen – and BioLife Solutions CTO Sean Werner says the field still treats what happens after manufacturing as an afterthought.
Most cell therapies arrive at the patient frozen – and BioLife Solutions CTO Sean Werner says the field still treats what happens after manufacturing as an afterthought.